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Abstract
Background: In 1999 a four-level hierarchy of evidence was promoted by the National Health and
Medical Research Council in Australia. The primary purpose of this hierarchy was to assist with
clinical practice guideline development, although it was co-opted for use in systematic literature
reviews and health technology assessments. In this hierarchy interventional study designs were
ranked according to the likelihood that bias had been eliminated and thus it was not ideal to assess
studies that addressed other types of clinical questions. This paper reports on the revision and
extension of this evidence hierarchy to enable broader use within existing evidence assessment
systems.
Methods: A working party identified and assessed empirical evidence, and used a commissioned
review of existing evidence assessment schema, to support decision-making regarding revision of
the hierarchy. The aim was to retain the existing evidence levels I-IV but increase their relevance
for assessing the quality of individual diagnostic accuracy, prognostic, aetiologic and screening
studies. Comprehensive public consultation was undertaken and the revised hierarchy was piloted
by individual health technology assessment agencies and clinical practice guideline developers. After
two and a half years, the hierarchy was again revised and commenced a further 18 month pilot
period.
Results: A suitable framework was identified upon which to model the revision. Consistency was
maintained in the hierarchy of "levels of evidence" across all types of clinical questions; empirical
evidence was used to support the relationship between study design and ranking in the hierarchy
wherever possible; and systematic reviews of lower level studies were themselves ascribed a
ranking. The impact of ethics on the hierarchy of study designs was acknowledged in the
framework, along with a consideration of how harms should be assessed.
Conclusion: The revised evidence hierarchy is now widely used and provides a common standard
against which to initially judge the likelihood of bias in individual studies evaluating interventional,
diagnostic accuracy, prognostic, aetiologic or screening topics. Detailed quality appraisal of these
individual studies, as well as grading of the body of evidence to answer each clinical, research or
policy question, can then be undertaken as required.
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Background
The corner-stone of evidence-based healthcare and health
technology assessment is critical appraisal of the evidence
underpinning a finding. Different methods are available
for assessing the quality of the evidence, including rank-
ing the body of evidence according to a hierarchy which
indicates the level of bias associated with the different
study designs that have contributed to the evidence-base.
In Australia, the standard evidence hierarchy in use since
1999 has been the National Health and Medical Research
Council (NHMRC) Designation of Levels of Evidence [1].
This hierarchy ranks the body of evidence into four levels
– from systematic reviews of randomised trials at the top
of the hierarchy, to case series and case reports at the bot-
tom of the hierarchy (Table 1). Its intended purpose was
to summarise the body of evidence for interventions (eg
treatment effectiveness). Through widespread use in clin-
ical practice guideline development and health technol-
ogy assessment, it became increasingly clear that: i) the
hierarchy was being used to address research questions
that did not relate to interventions; ii) the hierarchy –
which is primarily concerned with the association
between bias and study design characteristics – was being
relied upon for the entire evidence appraisal rather than
there being a standardised appraisal of study quality as
suggested [2]; and iii) that although the aim was to use the
hierarchy to summarise the entire body of evidence – this
was occurring rather haphazardly in practice.
This paper describes the first stage of developing a hierar-
chy to rank the quality of individual  study designs to
address different types of questions. The second stage of
developing or adapting a simple, intuitive system to grade
the entire body of evidence is discussed elsewhere [3,4], and
will be the subject of a forthcoming publication.
The existing hierarchy
The existing NHMRC hierarchy of evidence was devel-
oped as part of a comprehensive series of handbooks
which outlined the methods for evaluating evidence and
developing and disseminating clinical practice guidelines
[1,2,5-9].
These handbooks recommended that the body of evi-
dence should be assessed along three dimensions:
strength, size of effect and clinical relevance. In this
schema the strength of evidence was determined by the
level of evidence, the quality of the evidence and its statis-
tical precision. It was further assumed that the results from
a 'body of evidence' could be distilled down to a single
size of effect, with associated statistical precision and that
the clinical relevance of this result could be determined eg
a pooled relative risk and confidence interval obtained
through meta-analysis. The evidence level, designated
according to the hierarchy (Table 1), assessed the likeli-
hood that the 'body of evidence' producing this single size
of effect was affected by bias.
It became clear on applying this schema that the available
evidence-base for clinical practice guidelines and health
technology assessments was often not amenable to meta-
analysis. Thus statistical synthesis for each of the outcomes
of interest into one estimate of effect, with associated sta-
tistical precision and determination of clinical relevance,
was often not possible. As a consequence, in practice, the
dimensions of evidence were often applied to individual
studies and were complemented with a narrative synthesis
of the overall findings from the body of evidence. The dif-
ficulty with this approach was that the original hierarchy
of evidence was not designed, nor worded, to refer to the
strength of the evidence obtained from individual studies.
Further, the hierarchy was designed to assess evidence
from intervention studies that evaluated therapeutic effec-
tiveness. It was therefore not appropriate for assessing
studies addressing diagnostic accuracy, aetiology, progno-
sis or screening interventions. The study designs best
suited to answer these types of questions are not always
the same, or presented in the same order, as that given in
the original NHMRC hierarchy of evidence. It was clear
that an alternative approach to appraising evidence was
needed.
The NHMRC therefore created a working party of clinical
practice guideline developers, health technology assess-
ment producers and methodologists (the Working Party)
Table 1: Designations of levels of evidence [1]
Level of evidence Study design
I Evidence obtained from a systematic review of all relevant randomised controlled trials
II Evidence obtained from at least one properly-designed randomised controlled trial
III-1 Evidence obtained from well-designed pseudorandomised controlled trials (alternate allocation or some other method)
III-2 Evidence obtained from comparative studies (including systematic reviews of such studies) with concurrent controls and 
allocation not randomised, cohort studies, case-control studies, or interrupted time series with a control group
III-3 Evidence obtained from comparative studies with historical control, two or more single arm studies, or interrupted time 
series without a parallel control group
IV Evidence obtained from case series, either post-test or pre-test/post-testBMC Medical Research Methodology 2009, 9:34 http://www.biomedcentral.com/1471-2288/9/34
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to develop a revised hierarchy of evidence for individual
studies (first stage) which addressed these issues, as well
as a method for appraising the body of evidence (second
stage) that could be used by guideline developers and oth-
ers.
The objective of the first stage was to create a framework
that aligned as closely as possible with the original evi-
dence hierarchy – to minimise confusion for current users
and maintain consistency with previous use of the hierar-
chy – but which could also rank individual studies
addressing questions other than therapeutic effectiveness.
Due consideration was to be given to methods used by
other organisations to develop "levels of evidence", in
order to minimise duplication of effort.
Methods
Recognising the need for an updated hierarchy of evi-
dence, a review was conducted of existing frameworks for
assessing non-randomised and non-interventional evi-
dence that are used by Health Technology Assessment
(HTA) agencies and guideline developers world-wide
[10]. This internal report commissioned by the NHMRC,
and conducted by HTanalysts, provided a resource for the
NHMRC and the Working Party to enable revision of the
current hierarchy of evidence. The aim was to adapt, if
possible, an existing evidence hierarchy or hierarchies.
The report searched for comprehensive evidence frame-
works that incorporated non-intervention evidence via
HTA and Guideline group websites that were identified
through the membership of the International Network of
Agencies for Health Technology Assessment (INAHTA)
and the Guidelines International Network (GIN) (see
Appendix). Bibliographies of identified publications were
examined and targeted Medline/EMBASE searches were
conducted. Frameworks were included if they were pub-
lished in English, were developed by a reputable HTA or
guideline agency, and contained guidance on at least one
of the methodological processes involved in undertaking
an evidence-based assessment (Guideline, HTA or system-
atic review).
The identified frameworks were then used to inform the
revision of the NHMRC evidence hierarchy. Six key factors
were considered integral to this revision process, specifi-
cally that:
1. the hierarchy addressed all types of questions and
was not limited to treatment effectiveness alone;
2. the levels I-IV were maintained and aligned as
closely as possible with the current NHMRC (treat-
ment effectiveness) hierarchy;
3. the hierarchy related to individual studies rather
than a body of evidence (given a multi-factorial
method of "grading" the body of evidence was being
developed/adapted concurrently via the NHMRC
Working Party);
4. the hierarchy remained broadly consistent across
types of question;
5. empirical evidence supported the placement of a
particular study design in the evidence hierarchy wher-
ever possible – that is, the relationship between study
design and bias for each clinical or research question
had been assessed empirically; or if not, there were
good theoretical grounds for such placement in the
hierarchy; and
6. subjective terms regarding the "quality" of studies
eg "well designed", "properly designed" would be
removed. The level of evidence would be assessed on
the basis of study design characteristics alone. Deter-
mination of the overall "quality" of the study would
be independently determined using appropriate – and
validated, where possible – checklists suitable for each
study design and question.
The "Levels" subgroup of the Working Party addressed
each of these criteria while drafting a revision of the evi-
dence hierarchy. This first iteration of the hierarchy was
slightly modified after consultation with other methodo-
logical experts within the wider Working Party. A second
iteration of the hierarchy was presented to Australian and
New Zealand evaluators undertaking health technology
assessments for the Australian Medical Services Advisory
Committee (MSAC). Other international experts on evi-
dence appraisal were contacted and provided feedback on
the hierarchy. These suggestions were discussed and some
substantial revisions – particularly concerning the diag-
nostic accuracy evidence hierarchy – were incorporated
into a version of the hierarchy that was suitable for pilot-
ing.
The hierarchy was piloted by NHMRC clinical practice
guideline developers and health technology assessment
evaluation groups in Australia and New Zealand from
November 2004 until June 2007. Public consultation
throughout this period was invited through the medium
of international conferences and workshops – specifically
the Cochrane Colloquium and the Health Technology
Assessment international (HTAi) conference [11-13] –
and through the NHMRC website. With the website, a
feedback form allowing free text responses to a series of
questions regarding the utility and adaptability of the
revised hierarchy was provided, along with a section for
suggested methods for improving the hierarchy. The hier-BMC Medical Research Methodology 2009, 9:34 http://www.biomedcentral.com/1471-2288/9/34
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archy was amended and a further pilot stage was then con-
ducted from February 2008 to February 2009. In total,
approximately a dozen responses were submitted through
the website, predominantly by individuals or organisa-
tions that had trialled the new evidence hierarchy.
Results
Identifying possible frameworks for adaptation
The 2004 report commissioned by the NHMRC identified
18 evidence frameworks that were relevant for clinical
evaluation of non-interventional evidence at that time
[10]. Three of the evidence evaluation frameworks were
found to use a hierarchy that related to questions other
than treatment or intervention effectiveness. The National
Institute for Clinical Excellence (NICE) provided a hierar-
chy that used levels of evidence for assessment of thera-
peutic effectiveness (based on those developed by the
Scottish Intercollegiate Guidelines Network – SIGN) as
well as for diagnostic accuracy [14]. The National Health
Service Centre for Reviews and Dissemination (NHS
CRD) used a framework that included levels of evidence
for assessing questions of effectiveness, diagnostic accu-
racy, and efficiency [15]. Finally, the Centre for Evidence
Based Medicine (CEBM) hierarchy included levels of evi-
dence for assessing questions of therapy/prevention and
aetiology/harm, prognosis, diagnosis, differential diagno-
sis/symptom prevalence, and economic and decision
analyses [16].
In terms of addressing different types of questions, the
CEBM framework was found to be the most comprehen-
sive and a suitable evidence hierarchy upon which to
model the revised NHMRC hierarchy of evidence,
although all three provided useful information.
The revised NHMRC hierarchy
Each of the six key factors considered integral to a revised
NHMRC evidence hierarchy were adopted. Five separate
research areas were addressed – interventions, diagnostic
accuracy, prognosis, aetiology and screening.
A greatly expanded table was created, largely based on the
design of the CEBM framework, which included five sep-
arate columns for each of the different research areas (see
Additional file 1). However, even though the CEBM lay-
out was very closely followed in the revised NHMRC hier-
archy, the number of research questions addressed and
description of studies did differ markedly from the CEBM
framework. Empirical evidence of study design biases and
epidemiological theory were used to rank the study
designs within each research area. It was suggested that
when referring to studies designated a level of evidence
according to the revised NHMRC hierarchy, both the level
and corresponding research area or question should be
used eg. level II intervention evidence; level IV diagnostic
evidence; level III-2 prognostic evidence.
To support users of the revised NHMRC evidence hierar-
chy, explanatory notes (see Additional file 1) and a glos-
sary of study designs and terminology (see Additional file
2) were developed and adapted from the NHMRC hand-
books [1,2,5-9]. The explanatory notes provide the con-
text for the evidence hierarchy, with guidance on how to
apply and present the levels of evidence. The glossary pro-
vides a definition of each of the given study designs.
Discussion
The revised NHMRC hierarchy of evidence largely
addresses the issues which brought about its develop-
ment. This hierarchy was developed using a combination
of evidence, theory and consultation. The Working Party
was able to successfully achieve its aim of providing a
practical and usable tool for evidence-based healthcare
practitioners and researchers. A number of special consid-
erations were addressed in the development of this revised
hierarchy, and some limitations were acknowledged
when designing the hierarchy.
Limitations
The evidence-base underpinning the development of a
hierarchy such as this is limited. For intervention research
questions there were some studies and a systematic review
showing the degree of bias associated with observational
and non-randomised studies, in comparison to ran-
domised controlled trials [17-19]. However, for diagnos-
tic research questions, at the time of developing the
hierarchy we were aware of only one study on design-
related bias associated with diagnostic studies [20]. In
instances where the evidence was lacking to determine
placement of the study design in the hierarchy, the CEBM
evidence framework was used, along with epidemiology
texts [21] and consensus expert opinion.
An evidence hierarchy addressing individual studies,
alone, cannot provide interpretation of the results of a
'body of evidence' and the various contextual factors that
can impinge on the interpretation of results (eg external
validity/applicability). The 'Working Party' believes that
any assessment of evidence underpinning a question
involves three steps:
1. determine the level of evidence of individual studies
addressing that question and rank the evidence accord-
ingly;
2. appraise the quality of the evidence within each ranking
using basic clinical epidemiology and biostatistical princi-
ples outlined in widely available critical appraisal check-
lists and tools; andBMC Medical Research Methodology 2009, 9:34 http://www.biomedcentral.com/1471-2288/9/34
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3. synthesise the findings from steps 1 and 2 and give
greatest weight to the highest quality/highest ranked evi-
dence. After including consideration of contextual factors,
make a clear and transparent decision or recommenda-
tion regarding the strength and applicability of the find-
ings from the body of evidence, and grade that
recommendation.
Steps 1 and 2 are addressed in this paper. Step 3 was
undertaken by the NHMRC Working Party through creat-
ing a process and system for classifying and grading the
body of evidence that takes into account dimensions
other than the internal validity of the studies – an issue
which has received similar attention in other countries
[22,23]. Progress on other grading systems to date has pri-
marily centred on therapeutic safety and effectiveness
research questions [24,25], although there have been
recent moves towards explicitly incorporating diagnostic
evidence [26]. The NHMRC Working Party has developed
a multi-dimensional system to grade the evidence and
develop recommendations in a user-friendly manner but
which also addresses various types of research question
(through use of this revised NHMRC evidence hierarchy
as an intermediary step). This "grading" process is
reported elsewhere and will be the subject of a subsequent
publication [3,4].
While the revised hierarchy described in this paper has
greatly expanded the types of studies that can be assigned
a level of evidence, it does not cover qualitative research
or economic analysis. There are existing hierarchies of evi-
dence for economic analysis, although it is unclear if the
methodological basis for the ranking within these hierar-
chies is supported by evidence and theory [15,16]. Should
there be an expressed need to expand the revised NHMRC
hierarchy to include economic analysis, this can occur
when the NHMRC handbooks are updated.
Methods for synthesising qualitative research evidence are
still being developed by groups such as the Cochrane Col-
laboration [27] and others [28,29]. In this context, critical
appraisal guides and hierarchies of qualitative evidence
have begun to appear in the literature [30]. A proper con-
sideration of these issues was beyond the scope of this
project and outside the methodological expertise of the
Working Party. However, this should be addressed by
investigators with appropriate expertise in qualitative
research methods as part of the NHMRC handbook
updates.
Special considerations
1. Systematic reviews of lower level evidence
In general, the Working Party took the view that system-
atic reviews should only be assigned a level of evidence as
high as the studies contained therein. Even the best qual-
ity systematic reviews will still only be able to answer a
research question on the basis of the evidence it has col-
lated and synthesised. Thus any overall conclusions will
be affected by the internal validity of the primary research
evidence included. However, consistent with the original
NHMRC hierarchy of evidence, Level I of the revised hier-
archy was retained as a systematic review of all relevant
level II studies, recognising that meta-analysis of Level II
studies can increase the precision of the findings of indi-
vidual Level II studies [31].
2. Studies of diagnostic test accuracy
The effectiveness of a diagnostic test or a screening test
requires either direct evidence ie the impact of the test on
patient health outcomes (outlined in the 'Intervention'
and 'Screening' columns, respectively, in the revised hier-
archy) [26] or, if certain conditions are fulfilled, the link-
ing of evidence of diagnostic test accuracy (assessed using
the 'Diagnostic accuracy' column in the hierarchy) with
evidence of change in management and the likely effect of
that change in management on patient health outcomes
(assessed using the 'Intervention' column in the revised
hierarchy) [32,33].
The development of levels of evidence for studies of diag-
nostic accuracy proved to be more difficult than for the
other types of research question. In studies of diagnostic
accuracy the basic study design is cross-sectional, in which
all participants receive both the index test and the refer-
ence standard. In order to rank the validity of each indi-
vidual study's results it was found that a more specific
discussion of study design was required. To aid with the
interpretation and ranking of studies comprehensive
explanatory notes were developed. To some extent the
degree of bias introduced by a particular study design fea-
ture is dependent upon both the disease and the diagnos-
tic test context under investigation. Well-developed
critical appraisal skills of the reviewers of diagnostic test
interventions are therefore essential. Methods for assess-
ing diagnostic test accuracy by systematic review and
meta-analysis have been progressing over a relatively
short period of time (especially compared with studies of
therapeutic effectiveness) [34-37]. As this methodology
matures, the descriptive nature of the 'Diagnostic accu-
racy' levels in the revised hierarchy may no longer be
required, as study designs in which bias is minimised are
recognised (and possibly even named) as is currently the
case with studies of therapeutic effectiveness.
3. Correct classification of the research question
One other difficulty has been noted with use of the evi-
dence hierarchy. The difficulty is not with the study
designs or the ranking of the study designs, but rather with
distinguishing between an aetiological and prognostic
research question – and thus correct use of the relevantBMC Medical Research Methodology 2009, 9:34 http://www.biomedcentral.com/1471-2288/9/34
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hierarchy. Both aetiology and prognosis relate to an iden-
tification of risk factors for an outcome and so the relevant
study designs are quite similar. The key when determining
if a research question is aetiological or prognostic is to
identify the population of interest. For prognostic ques-
tions, all the population has the condition/disease and
the aim is to determine what factors will predict an out-
come for that population (eg survival) [2]. For example,
"What are the risk factors for suicide in adolescent depres-
sion?" These factors can be causal (eg a treatment modal-
ity), effect modifiers (eg age) or just associations or
markers. For aetiology questions, the key is ensuring the
population of interest do not or did not have the condi-
tion/disease at some point in time, so that causality of the
risk factor can be determined [2]. For example, "What are
the risk factors for adolescent depression?" The explana-
tory notes to the hierarchy cannot make this distinction
between aetiology and prognosis completely clear
because of the degree of overlap in the relevant study
designs.
4. Assessment of study quality
The revised hierarchy of evidence is intended to be used as
just one component in determining the strength of the
evidence; that is, determining the likelihood of bias from
the study design alone. This component is seen as a broad
indicator of likely bias and can be used to roughly rank
individual studies within a body of evidence. However,
study quality within each of the levels of evidence needs
to be assessed more rigorously. The Working Party
believes that there are so many factors affecting the inter-
nal validity of study results (e.g. bias, confounding, results
occurring by chance, impact of drop-outs), with different
factors affecting different study designs, that a proper
assessment of study quality can only occur with the use of
an appropriate and/or validated checklist suitable for each
study design or research question [2,15,25,37,38]. In the
accompanying documentation to the revised evidence
hierarchy, suggestions have been made as to the appropri-
ate checklists for a formal critical appraisal of studies
addressing the different types of research question [4].
5. Ethical considerations
The impact of ethics on the hierarchy of study designs was
acknowledged in the revised evidence hierarchy. Separate
columns for aetiology and intervention research ques-
tions were produced in order to address trial feasibility
and ethical issues. Explanatory notes appended to the
hierarchy indicate that if it is possible and/or ethical to
determine a causal relationship using experimental evi-
dence, then the 'Intervention' hierarchy of evidence
should be used. However, if it is only possible and/or eth-
ical to determine a causal relationship using observational
evidence (for example if it is not ethical to allocate groups
to a potentially harmful exposure such as nuclear radia-
tion), then the 'Aetiology' hierarchy of evidence should be
used [39,40]. In the latter scenario, the highest level of evi-
dence that could be used to address the question would be
observational and not experimental.
6. Assessment of harms/safety
There is guidance in the explanatory notes about how to
deal with the evaluation of comparative harms and safety
in the research area of interest. Assessment of comparative
harms/safety should occur according to the hierarchy pre-
sented for each of the research questions, with the proviso
that this assessment occurs within the context of the topic
being assessed. Some harms (as well as some effectiveness
outcomes) are rare and cannot feasibly be captured within
randomised controlled trials [41,42], in which case lower
levels of evidence may be the only type of evidence that is
practically achievable; physical harms and psychological
harms may need to be addressed by different study
designs [43]; harms from diagnostic testing include the
likelihood of false positive and false negative results
[44,45]; harms from screening include the likelihood of
false alarm and false reassurance results [46].
No single evidence-framework can address all of the safety
and effectiveness issues associated with different research
areas. The aim of the explanatory note was to explicitly
recognise that these differences will occur and to adapt the
hierarchy where necessary.
Conclusion
Given the extensive pilot process – four years – this new
evidence hierarchy is now the standard for judging "levels
of evidence" for the purposes of health technology assess-
ment and clinical practice guideline development in Aus-
tralia.
Although this broad ranking tool for assessing study qual-
ity is intended for use as an intermediary step within the
new NHMRC system to grade the body of evidence
addressing a clinical, research or policy question [4], it can
be applied within existing grading systems eg GRADE
[47], SIGN [25] with the benefit of allowing a ranking of
evidence that addresses research questions or areas other
than therapeutic effectiveness.
This tool is particularly advantageous for structuring a
narrative meta-synthesis of results in an evidence report or
health technology assessment. Studies and study results
can initially be ranked by study design (evidence level)
using the revised evidence hierarchy, and then be further
ranked within each evidence level with the use of appro-
priate and validated quality appraisal checklists. A grading
of the body of evidence can then be applied, if relevant.BMC Medical Research Methodology 2009, 9:34 http://www.biomedcentral.com/1471-2288/9/34
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